Leishmaniasis: treatment, drug resistance and emerging therapies

References

• WHO. Control of the leishmaniasis. Geneva: World Health Organization; 2010.
   Google Scholar
• Sundar S, Chakravarty J. Leishmaniasis: an update of current pharmacotherapy. Expert Opin Pharmacother. 2013;14(1):53–63.
   PubMed Web of Science ®Google Scholar
• Thakur C, Kumar K. Post kala-azar dermal leishmaniasis: a neglected aspect of kala-azar control programmes. Ann Trop Med Parasitol. 1992;86(4):355–359.
   PubMed Web of Science ®Google Scholar
• Zijlstra EE, Musa AM, Khalil EA, et al. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis. 2003;3(2):87–98.
   PubMed Web of Science ®Google Scholar
• National Vector Borne Disease Control Programme (NVBDCP). Operational guidelines on Kala-Azar (Visceral Leishmaniasis) elimination in India - 2015. Ministry of Health and Family Welfare, Government of India, 2015.
   Google Scholar
• Alvar J, Canavate C, Gutierrez-Solar B, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev. 1997;10(2):298–319.
   PubMed Web of Science ®Google Scholar
• Desjeux P, Alvar J. Leishmania/HIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol. 2003;97(Suppl 1):3–15.
   PubMed Web of Science ®Google Scholar
• Alvar J, Aparicio P, Aseffa A, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev. 2008;21(2):334–359. table of contents.
   PubMed Web of Science ®Google Scholar
• Burza S, Sinha PK, Mahajan R, et al. Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India. PLoS Negl Trop Dis. 2014;8(1):e2603.
   PubMed Web of Science ®Google Scholar
• Burza S, Mahajan R, Sanz MG, et al. HIV and visceral leishmaniasis coinfection in Bihar, India: an underrecognized and underdiagnosed threat against elimination. Clin Infect Dis. 2014;59(4):552–555.
   PubMed Web of Science ®Google Scholar
• Cota GF, de Sousa MR, de Mendonca AL, et al. Leishmania-HIV co-infection: clinical presentation and outcomes in an urban area in Brazil. PLoS Negl Trop Dis. 2014;8(4):e2816.
   PubMed Web of Science ®Google Scholar
• Luz JGG, Naves DB, Carvalho AG, et al. Visceral leishmaniasis in a Brazilian endemic area: an overview of occurrence, HIV coinfection and lethality. Rev Inst Med Trop Sao Paulo. 2018;60:e12.
   PubMed Web of Science ®Google Scholar
• Mengesha B, Endris M, Takele Y, et al. Prevalence of malnutrition and associated risk factors among adult visceral leishmaniasis patients in Northwest Ethiopia: a cross sectional study. BMC Res Notes. 2014;7:75.
   PubMedGoogle Scholar
• Mengistu G, Ayele B. Visceral Leishmaniasis and HIV co-infection in patients admitted to Gondar University Hospital, Northwest Ethiopia. Ethiop J Health Dev. 2007;21(1):53–60.
   Google Scholar
• Alvar J, Velez ID, Bern C, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7(5):e35671.
   PubMed Web of Science ®Google Scholar
• Freitas-Junior LH, Chatelain E, Kim HA, et al. Visceral leishmaniasis treatment: what do we have, what do we need and how to deliver it? Int J Parasitol Drugs Drug Resist. 2012;2:11–19.
   PubMed Web of Science ®Google Scholar
• Tiuman TS, Santos AO, Ueda-Nakamura T, et al. Recent advances in leishmaniasis treatment. Int J Infect Dis. 2011;15(8):e525–32.
   PubMed Web of Science ®Google Scholar
• Aikat BK, Sahaya S, Pathania AG, et al. Clinical profile of cases of kala-azar in Bihar. Indian J Med Res. 1979;70:563–570.
   PubMed Web of Science ®Google Scholar
• Thakur CP, Kumar M, Singh SK, et al. Comparison of regimens of treatment with sodium stibogluconate in kala-azar. Br Med J (Clin Res Ed). 1984;288(6421):895–897.
   PubMedGoogle Scholar
• Jha TKSN, Jha SN. Therapeutic use of sodium stibogluconate in kala-azar from some hyperendemic districts of N. Bihar, India. J Assoc Physicians India. 1992;40:868.
   Google Scholar
• Faraut-Gambarelli F, Piarroux R, Deniau M, et al. In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Antimicrob Agents Chemother. 1997;41(4):827–830.
   PubMed Web of Science ®Google Scholar
• Rijal S, Chappuis F, Singh R, et al. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans R Soc Trop Med Hyg. 2003;97(3):350–354.
   PubMed Web of Science ®Google Scholar
• Sundar S, Thakur BB, Tandon AK, et al. Clinicoepidemiological study of drug resistance in Indian kala-azar. Bmj. 1994;308(6924):307.
   PubMedGoogle Scholar
• Ritmeijer K, Dejenie A, Assefa Y, et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis. 2006;43(3):357–364.
   PubMed Web of Science ®Google Scholar
• Diro E, Lynen L, Mohammed R, et al. High parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected adults in Ethiopia. PLoS Negl Trop Dis. 2014;8(5):e2875.
   PubMed Web of Science ®Google Scholar
• Ponte-Sucre A, Gamarro F, Dujardin J-C, et al. Drug resistance and treatment failure in leishmaniasis: a 21st century challenge. PLoS Negl Trop Dis. 2017;11(12):e0006052.
   PubMed Web of Science ®Google Scholar
• Thakur C, Singh R, Hassan S, et al. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans R Soc Trop Med Hyg. 1999;93(3):319–323.
   PubMed Web of Science ®Google Scholar
• Mishra M, Biswas UK, Jha DN, et al. Amphotericin versus pentamidine in antimony-unresponsive kala-azar. Lancet. 1992;340(8830):1256–1257.
   PubMed Web of Science ®Google Scholar
• Sundar S, Chakravarty J, Agarwal D, et al. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med. 2010;362(6):504–512.
   PubMed Web of Science ®Google Scholar
• Tamiru A, Tigabu B, Yifru S, et al. Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia. BMC Infect Dis. 2016;16(1):548.
   PubMedGoogle Scholar
• Ritmeijer K, Ter Horst R, Chane S, et al. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence. Clin Infect Dis. 2011;53(12):e152–8.
   PubMed Web of Science ®Google Scholar
• Solomon M, Pavlotsky F, Leshem E, et al. Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica. J Eur Acad Dermatol Venereol. 2011;25(8):973–977.
   PubMed Web of Science ®Google Scholar
• Layegh P, Rajabi O, Jafari MR, et al. Efficacy of topical liposomal amphotericin B versus intralesional meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. J Parasitol Res. 2011;2011:656523.
   PubMedGoogle Scholar
• Amato VS, Tuon FF, Camargo RA, et al. Can we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis? Am J Trop Med Hyg. 2011;85(5):818–819.
   PubMed Web of Science ®Google Scholar
• Amato VS, Tuon FF, Siqueira AM, et al. Treatment of mucosal leishmaniasis in Latin America: systematic review. Am J Trop Med Hyg. 2007;77(2):266–274.
   PubMed Web of Science ®Google Scholar
• Rocio C, Amato VS, Camargo RA, et al. Liposomal formulation of amphotericin B for the treatment of mucosal leishmaniasis in HIV-negative patients. Trans R Soc Trop Med Hyg. 2014;108(3):176–178.
   PubMed Web of Science ®Google Scholar
• Srivastava P, Prajapati VK, Rai M, et al. Unusual case of resistance to amphotericin B in visceral leishmaniasis in a region in India where leishmaniasis is not endemic. J Clin Microbiol. 2011;49(8):3088–3091.
   PubMed Web of Science ®Google Scholar
• Morizot G, Jouffroy R, Faye A, et al. Antimony to cure visceral leishmaniasis unresponsive to liposomal amphotericin B. PLoS Negl Trop Dis. 2016;10(1):e0004304.
   PubMed Web of Science ®Google Scholar
• Purkait B, Kumar A, Nandi N, et al. Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani. Antimicrob Agents Chemother. 2012;56(2):1031–1041.
   PubMed Web of Science ®Google Scholar
• Eichenberger A, Buechi AE, Neumayr A, et al. A severe case of visceral leishmaniasis and liposomal amphotericin B treatment failure in an immunosuppressed patient 15 years after exposure. BMC Infect Dis. 2017;17(1):81.
   PubMedGoogle Scholar
• Dorlo TP, Balasegaram M, Beijnen JH, et al. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother. 2012;67(11):2576–2597.
   PubMed Web of Science ®Google Scholar
• Sundar S, Singh A, Rai M, et al. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis. 2012;55(4):543–550.
   PubMed Web of Science ®Google Scholar
• Rijal S, Ostyn B, Uranw S, et al. Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clinl Infect Dis. 2013;56(11):1530–1538.
   PubMed Web of Science ®Google Scholar
• Rahman M, Ahmed B-N, Faiz MA, et al. Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh. Am J Trop Med Hyg. 2011;85(1):66–69.
   PubMed Web of Science ®Google Scholar
• Ostyn B, Hasker E, Dorlo TP, et al. Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia. PLoS One. 2014;9(6):e100220.
   PubMed Web of Science ®Google Scholar
• Rai K, Cuypers B, Bhattarai NR, et al. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain. MBio. 2013;4(5):e00611–13.
   PubMed Web of Science ®Google Scholar
• Srivastava S, Mishra J, Gupta AK, et al. Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India. Parasit Vectors. 2017;10(1):49.
   PubMed Web of Science ®Google Scholar
• Sundar S, Chakravarty J. An update on pharmacotherapy for leishmaniasis. Expert Opin Pharmacother. 2015;16(2):237–252.
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha T, Thakur CP, et al. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med. 2007;356(25):2571–2581.
   PubMed Web of Science ®Google Scholar
• Krause G, Kroeger A. Topical treatment of American cutaneous leishmaniasis with paramomycin and methylbenzethonium chloride: a clinical study under field conditions in Ecuador. Trans R Soc Trop Med Hyg. 1994;88(1):92–94.
   PubMed Web of Science ®Google Scholar
• El-On J, Halevy S, Grunwald MH, et al. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study. J Am Acad Dermatol. 1992;27(2):227–231.
   PubMed Web of Science ®Google Scholar
• Kim DH, Chung HJ, Bleys J, et al. Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials. PLoS Negl Trop Dis. 2009;3(2):e381.
   PubMed Web of Science ®Google Scholar
• Correia D, Macedo V, Carvalho E, et al. Comparative study of meglumine antimoniate, pentamidine isethionate and aminosidine sulfate in the treatment of primary skin lesions caused by Leishmania (Viannia) braziliensis. Rev Soc Bras Med Trop. 1996;29(5):447–453.
   PubMedGoogle Scholar
• Romero G, Lessa H, Macedo V, et al. Open therapeutic study with aminosidine sulfate in mucosal leishmaniasis caused by Leishmania (Viannia) braziliensis. Rev Soc Bras Med Trop. 1996;29(6):557–565.
   PubMedGoogle Scholar
• Romero GA, Lessa HA, Orge MG, et al. Mucosal leishmaniasis treatment with aminosidine sulfate: results of two year follow-up. Rev Soc Bras Med Trop. 1998;31(6):511–516.
   PubMedGoogle Scholar
• Llanos-Cuentas A, Echevarria J, Seas C, et al. Parenteral aminosidine is not effective for Peruvian mucocutaneous leishmaniasis. Am J Trop Med Hyg. 2007;76(6):1128–1131.
   PubMed Web of Science ®Google Scholar
• Chakravarty J, Sundar S. Drug resistance in leishmaniasis. J Glob Infect Dis. 2010;2(2):167.
   PubMedGoogle Scholar
• Alrajhi AA, Ibrahim EA, De Vol EB, et al. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med. 2002;346(12):891–895.
   PubMed Web of Science ®Google Scholar
• Dogra J, Saxena V. Itraconazole and leishmaniasis: a randomised double-blind trial in cutaneous disease. Int J Parasitol. 1996;26(12):1413–1415.
   PubMed Web of Science ®Google Scholar
• Momeni AZ, Jalayer T, Emamjomeh M, et al. Treatment of cutaneous leishmaniasis with itraconazole: randomized double-blind study. Arch Dermatol. 1996;132(7):784–786.
   PubMedGoogle Scholar
• Nassiri‐Kashani M, Firooz A, Khamesipour A, et al. A randomized, double‐blind, placebo‐controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis. J Eur Acad Dermatol Venereol. 2005;19(1):80–83.
   PubMed Web of Science ®Google Scholar
• Olliaro PL, Guerin PJ, Gerstl S, et al. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980–2004. Lancet Infect Dis. 2005;5(12):763–774.
   PubMed Web of Science ®Google Scholar
• Melaku Y, Collin SM, Keus K, et al. Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy. Am J Trop Med Hyg. 2007;77(1):89–94.
   PubMed Web of Science ®Google Scholar
• Kimutai R, Musa AM, Njoroge S, et al. Safety and effectiveness of sodium stibogluconate and paromomycin combination for the treatment of visceral leishmaniasis in Eastern Africa: results from a pharmacovigilance programme. Clin Drug Investig. 2017;37(3):259–272.
   PubMed Web of Science ®Google Scholar
• Seifert K, Croft SL. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Antimicrob Agents Chemother. 2006;50(1):73–79.
   PubMed Web of Science ®Google Scholar
• Sundar S, Rai M, Chakravarty J, et al. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clinl Infect Dis. 2008;47(8):1000–1006.
   PubMed Web of Science ®Google Scholar
• Sundar S, Sinha PK, Rai M, et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet. 2011;377(9764):477–486.
   PubMed Web of Science ®Google Scholar
• Rahman R, Goyal V, Haque R, et al. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh. PLoS Negl Trop Dis. 2017;11(5):e0005635.
   PubMed Web of Science ®Google Scholar
• Wasunna M, Njenga S, Balasegaram M, et al. Efficacy and safety of AmBisome in combination with sodium stibogluconate or miltefosine and miltefosine monotherapy for African visceral leishmaniasis: phase II randomized trial. PLoS Negl Trop Dis. 2016;10(9):e0004880.
   PubMed Web of Science ®Google Scholar
• Romero GAS, Costa DL, Costa CHN, et al. Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: a multicenter, randomized, open label trial. PLoS Negl Trop Dis. 2017;11(6):e0005706.
   PubMed Web of Science ®Google Scholar
• Hendrickx S, Beyers J, Mondelaers A, et al. Evidence of a drug-specific impact of experimentally selected paromomycin and miltefosine resistance on parasite fitness in Leishmania infantum. J Antimicrob Chemother. 2016;71(7):1914–1921.
   PubMed Web of Science ®Google Scholar
• Hendrickx S, Van Den Kerkhof M, Mabille D, et al. Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum. PLoS Negl Trop Dis. 2017;11(5):e0005620.
   PubMed Web of Science ®Google Scholar
• Brito G, Dourado M, Guimarães LH, et al. Oral pentoxifylline associated with pentavalent antimony: a randomized trial for cutaneous leishmaniasis. Am J Trop Med Hyg. 2017;96(5):1155–1159.
   PubMed Web of Science ®Google Scholar
• Lessa HA, Machado P, Lima F, et al. Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. Am J Trop Med Hyg. 2001;65(2):87–89.
   PubMed Web of Science ®Google Scholar
• Machado PR, Lessa H, Lessa M, et al. Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clinl Infect Dis. 2007;44(6):788–793.
   PubMed Web of Science ®Google Scholar
• Ventin F, Cincurá C, Machado PRL. Safety and efficacy of miltefosine monotherapy and pentoxifylline associated with pentavalent antimony in treating mucosal leishmaniasis. Expert Rev Anti Infect Ther. 2018;16(3):219–225.
   PubMed Web of Science ®Google Scholar
• Arellano JLP, Cabrera MH, Alamo EP, et al. Tratamiento de las enfermedades parasitarias (I): protozoosis. Información Terapéutica del Sistema Nacional de Salud. 2007;31(1):3–16.
   Google Scholar
• Jameson MB, Rischin D, Pegram M, et al. A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. Cancer Chemother Pharmacol. 2010;65(4):791–801.
   PubMed Web of Science ®Google Scholar
• Wilkinson RS, Bot C, Kelly MJ, et al. Trypanocidal activity of nitroaromatic prodrugs: current treatments and future perspectives. Curr Top Med Chem. 2011;11(16):2072–2084.
   PubMed Web of Science ®Google Scholar
• Denny WA. Prodrugs for gene-directed enzyme-prodrug therapy (suicide gene therapy). Biomed Res Int. 2003;2003(1):48–70.
   Google Scholar
• Chen Y, Hu L. Design of anticancer prodrugs for reductive activation. Med Res Rev. 2009;29(1):29–64.
   PubMed Web of Science ®Google Scholar
• DNDi. Trial to determine efficacy of fexinidazole in visceral leihmaniasis patients in sudan. [cited 2013 Nov 12]. Available from: http://clinicaltrials.gov/show/NCT01980199
   Google Scholar
• DNDi. Fexinidazole/miltefosine combination (VL). [cited 2016]. Available from: https://www.dndi.org/diseases-projects/portfolio/completed-projects/fexinidazole-vl/
   Google Scholar
• Diacon AH, Dawson R, Du Bois J, et al. A phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob Agents Chemother. 2012;AAC:06111–06125.
   Google Scholar
• Sundar S, Chakravarty J. Investigational drugs for visceral leishmaniasis. Expert Opin Investig Drugs. 2015;24(1):43–59.
   PubMed Web of Science ®Google Scholar
• Kumar R, Sahoo GCPandey K, et al. Plga-peg encapsulated sitamaquine nanoparticles drug delivery system against leishmania donovani. Jsir. 2014;3:85-90.
   Google Scholar
• Gutiérrez V, Seabra AB, Reguera RM, et al. New approaches from nanomedicine for treating leishmaniasis. Chem Soc Rev. 2016;45(1):152–168.
   PubMed Web of Science ®Google Scholar
• Pham T, Loiseau P, Barratt G. Strategies for the design of orally bioavailable antileishmanial treatments. Int J Pharm. 2013;454(1):539–552.
   PubMedGoogle Scholar
• Saudagar P, Dubey VK. Carbon nanotube based betulin formulation shows better efficacy against Leishmania parasite. Parasitol Int. 2014;63(6):772–776.
   PubMed Web of Science ®Google Scholar
• Prajapati VK, Awasthi K, Yadav TP, et al. An oral formulation of amphotericin B attached to functionalized carbon nanotubes is an effective treatment for experimental visceral leishmaniasis. J Infect Dis. 2011;205(2):333–336.
   PubMed Web of Science ®Google Scholar
• López L, Vélez I, Asela C, et al. A phase II study to evaluate the safety and efficacy of topical 3% amphotericin B cream (Anfoleish) for the treatment of uncomplicated cutaneous leishmaniasis in Colombia. PLoS Negl Trop Dis. 2018;12(7):e0006653.
   PubMed Web of Science ®Google Scholar
• Akbari M, Oryan A, Hatam G. Application of nanotechnology in treatment of leishmaniasis: a review. Acta Trop. 2017;172:86–90.
   PubMed Web of Science ®Google Scholar
• Rodriguez F, Iniguez E, Pena GC, et al. Development of thiophene compounds as potent chemotherapies for the treatment of cutaneous leishmaniasis caused by leishmania major. Molecules. 2018;23:7.
   Web of Science ®Google Scholar
• Teixeira de Macedo Silva S, Visbal G, Lima Prado Godinho J, et al. In vitro antileishmanial activity of ravuconazole, a triazole antifungal drug, as a potential treatment for leishmaniasis. J Antimicrob Chemother. 2018.
   PubMed Web of Science ®Google Scholar
• DNDi. Miltefosine/Paromomycin combination for africa. [cited 2018 Aug]. Available from: https://www.dndi.org/diseases-projects/portfolio/miltefosine-paromomycin-combo/
   Google Scholar
• DNDi. New treatments for HIV/VL. [cited 2018 Aug]. Available from: https://www.dndi.org/diseases-projects/portfolio/hivvl/
   Google Scholar
• CTRI. A randomized trial of AmBisome® single therapy and combination of AmBisome® and miltefosine for the treatment of Kala Azar in HIV positive patients in India. [ cited 2017 Jan]. Available from: http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=11735
   Google Scholar
• Ramesh V, Katara G, Verma S, et al. Miltefosine as an effective choice in the treatment of post‐kala‐azar dermal leishmaniasis. Br J Dermatol. 2011;165(2):411–414.
   PubMed Web of Science ®Google Scholar
• DNDi. An open label, randomized, parallel arm clinical trial of two regimens to assess the safety and efficacy for treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) patients in Sudan. [cited 2018 Aug 22]. Available from: https://ichgcp.net/clinical-trials-registry/NCT03399955
   Google Scholar